2-(3-Aminopropyl)cyclopentan-1-one | 1354393-28-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(3-Aminopropyl)cyclopentan-1-one
• CAS: 1354393-28-4
• 化学式: C₈H₁₅NO
• mdl: MFCD19215594
• 分子量: 141.213
• InChiKey: NYPUQGQAHUBBMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  正癸酸 、 2-(3-Aminopropyl)cyclopentan-1-one 在 N,N'-羰基二咪唑 作用下， 以 乙酸乙酯 为溶剂， 反应 24.0h， 生成 N-[3-(2-oxocyclopentyl)propyl]decanamide
  参考文献：
  名称：

  [EN] INHIBITING HYDROCARBON HYDRATE AGGLOMERATION
  [FR] INHIBITION DE L'AGGLOMÉRATION D'HYDRATES D'HYDROCARBURES

  摘要：

  一种抑制碳氢化合物流体中天然气水合物形成的方法包括向碳氢化合物流体中添加一种气体水合物抗凝聚剂，该抗凝聚剂是一种可生物降解的抗凝聚剂，来源于天然存在的物质。

  公开号：

  WO2018218281A1

文献信息

• Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
  申请人：Batt G. Douglas

  公开号：US20050192276A1

  公开（公告）日：2005-09-01

  The present application describes modulators of MCP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein X, Z, a, b, c, d, bond g, n, s, R 1 , R 2 , R 4 , R 5 , R 10 , R 12 , and R 13 , are as defined above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

  本申请描述了公式(I)的MCP-1调节剂，或其立体异构体或药学上可接受的盐，其中X、Z、a、b、c、d、键g、n、s、R1、R2、R4、R5、R10、R12和R13如上所定义。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
• Substituted fused bicyclic amines as modulators of chemokine receptor activity
  申请人：Batt G. Douglas

  公开号：US20050197373A1

  公开（公告）日：2005-09-08

  The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 5 ′, R 6 , a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

  本申请描述了公式(Ia)和(Ib)的CCR3调节剂，或其药用盐形式，其中Z、R1、R2、R3、R4、R5、R5'、R6、a、b、c、d和u的定义如本文所述。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
• Synthesis of a 200-member library of squaric acid N-hydroxylamide amides
  作者：Julie Charton、Benoît P. Déprez、Rébecca F. Déprez-Poulain

  DOI：10.1016/j.bmcl.2008.08.025

  日期：2008.9

  We report here the parallel synthesis of 200 compounds based on squaric acid template. These compounds are obtained via a one-step solution-phase procedure starting from three squaric acid N-hydroxylamide esters precursors. The set of diverse reagents qualified (amines, anilines, amino-alcohols and amino-esters) makes this strategy suitable for the search of biologically active compounds. The library was screened on the zinc metalloenzyme ADAMTS-5 and hits with IC50 in the range of 1-50 mu M were identified. (C) 2008 Elsevier Ltd. All rights reserved.
• Heterocyclic aspartyl protease inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2343069B1

  公开（公告）日：2016-03-02
• US7230022B2
  申请人：——

  公开号：US7230022B2

  公开（公告）日：2007-06-12